Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen

Borrás-Blasco, Joaquı́n; Gracia-Pérez, Antonio; Casterá, M Dolores-Elvira; Rosique-Robles, J Dolores; Abad, Javier

doi:10.1517/14712598.2013.795942

Cited by 19 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, RA patients administering methotrexate with an AI experience less pain and prefer it over the PFS [21,22]. Selfinjection by AI is also preferred by patients using adalimumab [23,24], etanercept [25][26][27], and golimumab [28,29], as well as in other disease areas, such as diabetes and growth hormone deficiency [30][31][32].…”

Section: Discussionmentioning

confidence: 99%

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Domańska

VanLunen

Peterson

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Objectives: To compare the usability of a new certolizumab pegol (CZP) autoinjector with the adalimumab, etanercept, and golimumab devices in patients with rheumatoid arthritis. Methods: Two identical studies were performed in 2013 and 2016; patients performed a simulated selfinjection with the CZP autoinjector and the most up-to-date device versions at the time in a randomized, consecutive sequence. The primary end point was the ranking of the four autoinjectors in order of preference. Device usability and intuitiveness were assessed across a range of secondary and exploratory end points. Results: The 2013 and 2016 study populations included 76 patients each; a significant majority (2013: 67%; 2016: 59%) ranked the CZP autoinjector as their most preferred device (p < 0.001). Most patients agreed that the CZP autoinjector was easier to use, start, and manipulate, and were more willing to use it than the comparator devices (p < 0.001 for all pairwise comparisons with CZP). Likert score differences also favored the CZP autoinjector regarding how easy it was to determine injection completion. The CZP autoinjector was associated with a low rate of use error. Conclusions: In both studies, the CZP autoinjector was the preferred choice compared to the alternative devices and was associated with a high level of patient satisfaction. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Domańska

VanLunen

Peterson

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Several commercial subcutaneous products up to 1 mL are available, including Enbrel (Amgen, Thousand Oaks, CA), Humira (AbbVie, North Chicago, IL), Simponi (Janssen Biotech, Horsham, PA), and Stelaris (Janssen Biotech). [5][6][7][8][9] When the therapeutic dose can be formulated in 1 mL, prefilled syringes and autoinjectors typically serve as the preferred delivery systems for subcutaneous selfadministration. 6,10 To limit the injection volume to 1 mL, monoclonal antibody formulations often need to be formulated at high concentrations at !100 mg/mL.…”

Section: Introductionmentioning

confidence: 99%

Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery

Doughty¹,

Clawson²,

Lambert³

et al. 2016

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Switching from a prefilled syringe to an auto-injector was associated with improved treatment compliance and persistence; patients with chronic diseases reported that auto-injection devices were preferable over prefilled syringes because they were less painful and simpler to use [ 74 , 76 , 77 ]. In one study, a 30% increase was observed in the number of patients self-administrating medication after switching to an auto-injector, which in turn led to a decrease in the proportion of patients requiring outpatient visits or additional assistance [ 76 ].…”

Section: Resultsmentioning

confidence: 99%

A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences

et al. 2018

View full text Add to dashboard Cite

Chronic inflammatory diseases (CIDs) represent a substantial clinical and economic burden to patients, providers, payers and society overall. Biologics, such as tumor necrosis factor inhibitors (TNFi), have emerged as effective treatment options for patients with CIDs. However, the therapeutic potential of biologics is not always achieved in clinical practice, with results from studies examining the use of biologics in real-world settings suggesting lower levels of treatment effectiveness compared with clinical trial results. Using a targeted approach, this literature review demonstrates that compliance and persistence with biologic therapy is suboptimal and that this has implications for both clinical outcomes and treatment costs. The review identified a variety of predictors of treatment compliance and persistence, including increased age, female gender, presence of comorbidities, increased disease activity, longer disease duration, smoking, increased body mass index, higher biologic treatment dose, higher treatment cost and lower health-related quality-of-life scores. Patients often cited factors associated with medication delivery as a reason for non-compliance and non-persistence, and device-related improvements to treatment delivery were associated with higher rates of compliance and persistence. The articles identified in this review provide insights that have the potential to help guide the development of new solutions to improve disease management and optimize treatment regimens. This has the potential to benefit patients’ health by improving clinical outcomes and to reduce the burden to society by limiting the economic impact of patients’ disease.FundingUCB Pharma.Electronic supplementary materialThe online version of this article (10.1007/s12325-018-0759-0) contains supplementary material, which is available to authorized users.

show abstract

Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen

Cited by 19 publications

References 7 publications

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery

A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences

Contact Info

Product

Resources

About